NCT01245166View on ClinicalTrials.gov

A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus

PHASE3UnknownINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

December 31, 2011

Conditions
The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mgPlus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks inSubjects With Type 2 Diabetes Mellitus.
Interventions
DRUG

Acarbose

Acarbose 50 mg, per orem, thrice daily

DRUG

Metformin/Acarbose

Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily

Trial Locations (1)

40705

RECRUITING

Taichung Veterans General Hospital, Taichung

Sponsors
All Listed Sponsors
lead

Lotus Pharmaceutical

INDUSTRY

NCT01245166 - A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter